North China Pharmaceutical (SHA:600812) withdrew the product registration of its polymyxin B sulfate injection, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug was used for urinary tract, meningeal, and blood infections caused by the Pseudomonas aeruginosa bacteria, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments